Who Paid My Doc
Naglazyme
Biological Mps VI
NDC 68135-020-01
General payments
$71,069
Research payments
$376,343
Through program year 2025, $71,069 in general payments and $376,343 in research payments were reported against Naglazyme (Mps VI).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $866 | 2 |
| 2022 | General | $3,795 | 6 |
| 2022 | Research | $6,325 | 1 |
| 2021 | General | $2,270 | 4 |
| 2021 | Research | $237,712 | 12 |
| 2020 | General | $35,362 | 36 |
| 2020 | Research | $36,550 | 24 |
| 2019 | General | $28,777 | 209 |
| 2019 | Research | $95,757 | 15 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
257 general · 52 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.